However, as SPT1 depletion or Lmna deletion in MEFs, myriocin did not affect the PARPi-sensitivity of breast cancer cells that are proficient in BRCA1, such as MCF7 or MDA-MB-231, regardless of their p53 status (Supplementary Fig. 5a–d). Here, TP53 is linked to breast cancer.